Orthofix Medical Inc
$ 15.90
-0.13%
04 Dec - close price
- Market Cap 629,635,000 USD
- Current Price $ 15.90
- High / Low $ 15.99 / 15.73
- Stock P/E N/A
- Book Value 11.20
- EPS -3.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.25 %
- 52 Week High 20.48
- 52 Week Low 10.24
About
Orthofix Medical Inc. (OFIX) is a prominent global medical device company headquartered in Lewisville, Texas, specializing in advanced surgical and non-surgical solutions for spine and orthopedic applications. With a strong presence in key markets such as the United States, Italy, Germany, the United Kingdom, and Brazil, Orthofix is dedicated to enhancing patient outcomes through innovative technologies and biological products. Leveraging its robust research and development capabilities, the company is well-positioned to meet the dynamic needs of healthcare professionals, driving sustained growth in the competitive medical device sector.
Analyst Target Price
$22.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-08 | 2023-08-08 | 2023-05-09 | 2023-03-06 |
| Reported EPS | 0.1976 | -0.36 | -1.3549 | 0.0154 | 0.07 | 0.05 | 0.11 | 0.02 | 0.07 | 0.02 | -0.1 | 0.19 |
| Estimated EPS | -0.3315 | -0.41 | -0.2667 | -0.05 | -0.15 | -0.19 | -0.33 | -0.08 | -0.21 | -0.47 | -0.51 | 0.1 |
| Surprise | 0.5291 | 0.05 | -1.0882 | 0.0654 | 0.22 | 0.24 | 0.44 | 0.1 | 0.28 | 0.49 | 0.41 | 0.09 |
| Surprise Percentage | 159.6078% | 12.1951% | -408.024% | 130.8% | 146.6667% | 126.3158% | 133.3333% | 125% | 133.3333% | 104.2553% | 80.3922% | 90% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OFIX
2025-11-02 17:56:33
Orthofix and MTF Biologics have renewed and expanded their partnership, extending Orthofix’s exclusive marketing rights to the Trinity allograft line through 2032. The agreement also includes the development of a new demineralized bone matrix (DBM) to be marketed under Orthofix’s Legacy brand, enhancing their biologic portfolio for spine and orthopedic surgical applications. This collaboration aims to provide innovative solutions and value to customers and patients, with the Legacy DBM expected to be available in Q3 2022.
2025-10-18 10:26:36
Orthofix Medical, Inc. has formed a Golden Cross, a technical indicator suggesting a potential bullish trend. The stock has recently outperformed the S&P 500 in daily and weekly performance, despite a year-to-date decline. While recent activity is promising, the company still faces broader market challenges, and investors will monitor if this Golden Cross leads to sustained upward momentum.
2025-10-15 11:00:00
Orthofix Medical Inc. (NASDAQ:OFIX) announced its participation in several upcoming investor conferences. Massimo Calafiore, President and CEO, and Julie Andrews, CFO, will present at the UBS Global Healthcare Conference, Stifel Healthcare Conference, and Jefferies Global Healthcare Conference. Live and archived webcasts of the presentations will be available on the Orthofix Investor Relations Website.
2024-12-31 23:59:59
Orthofix Medical Inc. announced the appointment of Patrick Fisher as President of its Global Orthopedics business. Fisher, previously with Stryker Corporation and Wright Medical, brings extensive experience in commercial optimization and market expansion in the orthopedics sector. His appointment includes significant inducement grants of performance-based and time-based restricted stock units, and stock options.
2024-08-28 22:34:00
ClaimsFiler is reminding Orthofix Medical, Inc. (NasdaqGS: OFIX) investors with losses exceeding $100,000 that the lead plaintiff deadline for a securities class action lawsuit is October 21, 2024. The lawsuit alleges that Orthofix and its executives failed to disclose material information and violated federal securities laws, stemming from the termination of key executives due to "inappropriate and offensive conduct." This news led to a significant drop in Orthofix's share price.
2024-07-10 00:00:00
Orthofix Medical has received 510(k) clearance from the US FDA for its Fitbone Transport and Lengthening System, designed to treat large bone defects in the femur and tibia. This system uses a motorized intramedullary nail for minimally invasive implantation, allowing patients to manage bone distraction at home. The clearance is expected to expand surgical options for challenging trauma conditions.
